Pacific Edge shares fall 63% after Novitas decision

Pacific Edge shares fall 63% after Novitas decision
(Image: Pacific Edge)
Rebecca Howard
Cancer diagnostics company Pacific Edge has come out swinging against a decision by Novitas, the Medicare administrative contractor with jurisdiction for its US laboratory, that would end reimbursement for Cxbladder Triage, Detect and Monitor. The shares fell 63% to $0.050 in early trading Monday after a trading halt was lifted.According to Pacific Edge, Novitas continues to misunderstand the current standard of care in evaluating hematuria patients, fails to consider new peer-reviewed evidence and repeats its flawed analysis of the existi...

More Markets

Mainfreight, China optimism drive stocks higher
Markets Market Close

Mainfreight, China optimism drive stocks higher

Optimism for a thaw in US-China trade relations gave the NZ sharemarket a positive lift.

Jamie Gray 02 May 2025
Manawa says Prime's latest default will not hurt the company further
Markets

Manawa says Prime's latest default will not hurt the company further

Manawa Energy says the regulators' move to stop a defaulting retailer from trading will have no further impact on its earnings.In August 2024, Manawa stated that an unnamed electricity retailer had defaulted on its payment obligations to Manawa.It was later revealed that this...

Ian Llewellyn 02 May 2025
'Well played, Don': Mainfreight shares spike 12%
Markets

'Well played, Don': Mainfreight shares spike 12%

The freight company expects its full-year results to exceed the market consensus.

Oliver Lewis 02 May 2025